872714-60-8

Basic information

• Product Name: 3-amino-4-bromo-6-methoxyquinoline
• Synonyms: 3-amino-4-bromo-6-methoxyquinoline;3-Quinolinamine, 4-bromo-6-methoxy- ;4-BROMO-6-METHOXYQUINOLIN-3-AMINE
• CAS NO: 872714-60-8
• Molecular Formula: C10H9BrN2O
• Molecular Weight: 253.09526
• Mol File: 872714-60-8.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-amino-4-bromo-6-methoxyquinoline(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-4-bromo-6-methoxyquinoline(872714-60-8)
• EPA Substance Registry System: 3-amino-4-bromo-6-methoxyquinoline(872714-60-8)

Safety Data

• Hazardous Substances Data: 872714-60-8(Hazardous Substances Data)

Upstream product

• 872714-59-5 (4-bromo-6-methoxy-quinolin-3-yl)-carbamic acid tert-butyl ester 
• 872714-51-7 4-bromo-6-methoxy-quinoline-3-carboxylic acid 
• 75-65-0 tert-butyl alcohol 

Relevant articles and documents

INHIBITORS OF MALT1 AND USES THEREOF

Provided herein are compounds that inhibit MALTl, a protein whose activity is responsible for constitutive NF-κΒ signaling in certain cancers (e.g., activated B-cell diffuse large B-cell lymphoma (ABC-DLBCL)). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating MALTl -related diseases and disorders (e.g., cancer) with the compounds in a subject, by administering the compounds and/or compositions described herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

ANTIBACTERIAL AGENTS

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.